A Phase II Study to Determine the Efficacy and Safety of Allogeneic Human Chondrocytes Expressing TGF-beta 1 (TissueGene-C) in Patients With Grade 3 Chronic Degenerative Joint Disease of the Knee

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Mar 2018 According to a Kolon TissueGene media release, TissueGene changed its name to Kolon TissueGene.
11 May 2015 According to a TissueGene media release, data from this study were presented at the 12th World Congress of the International Cartilage Repair Society (ICRS) 2015.
11 May 2015 According to a TissueGene media release, data from this study were presented at the 18th meeting of the American Society of Gene & Cell Therapy (ASGCT) 2015.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com